Skip to main content

For Industry

You are here

UM Ventures, Baltimore Launchpad

  • New Venture Initiative

    A $2M SBIR Grant is Supporting Isoprene's Advancement

    The early-stage small molecule oncology company is developing therapeutics for triple negative breast cancer and other cancers.

    Learn More

Advancing UMB Startups

UM Ventures, Baltimore Launchpad works with faculty inventors to spin out startup companies around highly-promising UMB intellectual property. In this unique initiative, our experienced business development team – all of whom are employed by UMB – take management roles within the company and work alongside the inventors, helping them de-risk and advance the technology and company.

Successful Startups

Living Pharma

Living Pharma

Living Pharma was acquired by Lentigen Techology, a Miltenyi Biotec Company, in 2017, just two years after it was established. The immunotherapy company was developing a universal CAR-T cell therapy.


Isoprene Pharmaceuticals

Isoprene Pharmaceuticals was launched in 2018 and is developing small molecules for oncology and dermatology applications. In 2020, the company received investment from and entered into an exclusive licensing agreement with a strategic partner. In 2021, they were awarded a $2 million Phase II SBIR grant from the National Cancer Institute.



SurgiGYN was launched in 2016 to develop minimally invasive surgical devices for gynecological surgery. The company received two investments from a strategic partner before being acquired by that partner in early 2020.